A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma